Deborah Brown - Oncolytics Biotech Independent Director

ONC Stock  CAD 1.26  0.01  0.79%   

Director

Ms. Deborah M. Brown, B.Sc., M.B.A., is Director of the Company. In addition to being a Management Consultant since 2014, Ms. Brown is currently a Managing Partner at Accelera Canada, a specialty consultancy firm that assists emerging biopharma ventures inthe United States and Europe with the development and implementation of Canadian market strategies. She held progressively senior roles at EMD Serono from 2000 to 2014, including Executive Vice President of Neuroimmunology for the company U.S. operations, and President and Managing Director of the company Canadian operations. In 2012, Ms. Brown was Chair of the National Pharmaceutical Organization and served on its Board of Directors from 2007 to 2014. She currently sits on the Boards of Life Sciences Ontario, the Strategic Executive Advisory Council for Canadian Cancer Trials Group, and her local SPCA since 2017.
Tenure 7 years
Professional MarksMBA
Address 322 11th Avenue SW, Calgary, AB, Canada, T2R 0C5
Phone403 670 7377
Webhttps://www.oncolyticsbiotech.com
Brown holds an MBA from University of Western OntarioIvey School of Business, an Hons B.Sc. from the University of Guelph and completed the Merck executive development programme at the University of Hong Kong, INSEAD and Northwestern University Kellogg School of Management.

Oncolytics Biotech Management Efficiency

The company has return on total asset (ROA) of (0.7133) % which means that it has lost $0.7133 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.3822) %, meaning that it generated substantial loss on money invested by shareholders. Oncolytics Biotech's management efficiency ratios could be used to measure how well Oncolytics Biotech manages its routine affairs as well as how well it operates its assets and liabilities. As of the 4th of December 2024, Return On Tangible Assets is likely to drop to -0.75. In addition to that, Return On Capital Employed is likely to drop to -1.03. At this time, Oncolytics Biotech's Other Current Assets are very stable compared to the past year. As of the 4th of December 2024, Other Assets is likely to grow to 1.05, while Total Assets are likely to drop about 30.5 M.
Oncolytics Biotech has accumulated 423 K in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Oncolytics Biotech has a current ratio of 8.63, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Oncolytics Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Oncolytics Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Oncolytics Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Oncolytics to invest in growth at high rates of return. When we think about Oncolytics Biotech's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 6 records

DIRECTOR Age

Sheila FrameTheratechnologies
57
Paul PommierTheratechnologies
76
Dale WeilTheratechnologies
63
Gary LittlejohnTheratechnologies
64
Gerald LacosteTheratechnologies
75
Gilles CloutierTheratechnologies
69
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada. ONCOLYTICS BIOTECH operates under Biotechnology classification in Canada and is traded on Toronto Stock Exchange. Oncolytics Biotech (ONC) is traded on Toronto Exchange in Canada and employs 32 people. Oncolytics Biotech is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Oncolytics Biotech Leadership Team

Elected by the shareholders, the Oncolytics Biotech's board of directors comprises two types of representatives: Oncolytics Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncolytics. The board's role is to monitor Oncolytics Biotech's management team and ensure that shareholders' interests are well served. Oncolytics Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncolytics Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ger Amersfoort, Independent Director
FCA FCA, Consultant
Dr MBA, CEO President
Wayne Pisano, Independent Chairman of the Board
Jon Patton, Director Communication
Wayne MBA, Interim Board
Andrew Guttadauro, Global Head of Business Development and Presidentident, Oncolytics Biotech (U.S.) Inc.
Grey Wilkinson, Scientist Medicine
Andres Gutierrez, Chief Medical Officer
BBA FCA, Consultant
Matthew Coffey, President, Chief Executive Officer, Chief Operating Officer, Director
William Rice, Independent Director
Allison Hagerman, Vice President - Product Development
Edwin Levy, Independent Director
Alan Tuchman, Chief Medical Officer, Senior Vice President - Medical and Clinical Affairs
Amy Levin, Vice Operations
Kirk Look, Chief Financial Officer
Rita Laeufle, Chief Medical Officer
FACP FACP, Consultant
CA CA, Chief Officer
Linda Hohol, Independent Director
Deborah Brown, Independent Director
J Lievonen, Director
RN BSN, Vice Operations
Bernd Seizinger, Independent Director
PMP PEng, Vice Development
Angela Holtham, Independent Director
BBA CM, Consultant
Mary Dillahunty, Vice President - Intellectual Property
Leonard Kruimer, Independent Director
Michael Moore, Vice President Investor Relations & Corporate Communications
George Gill, Senior Vice President - Regulatory Affairs & Chief Safety Officer

Oncolytics Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oncolytics Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Oncolytics Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oncolytics Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncolytics Biotech will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Oncolytics Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oncolytics Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oncolytics Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oncolytics Biotech to buy it.
The correlation of Oncolytics Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oncolytics Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oncolytics Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oncolytics Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Oncolytics Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncolytics Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncolytics Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncolytics Biotech Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.
You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Please note, there is a significant difference between Oncolytics Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncolytics Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncolytics Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.